Voronoi, Inc. (310210.KQ) has a MoatMap StockRank of 13/100 based on Quality (26/100), Value (33/100), and Momentum (37/100) factor scores. The current signal is STRONG SELL.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment...
| Price | $129.41 |
| Market Cap | $2.3B |
| P/E (Forward) | -67.78 |
| Price/Book | 34.07 |
| Return on Equity | -69.9% |
| Return on Invested Capital | -29.4% |
| Debt/Equity | 38.78 |
| Gross Margin | 100.0% |
| Operating Margin | -824.0% |
| Free Cash Flow | $-18K |
Voronoi, Inc. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).